Category Archives: Psoriasis

Psoriasis Treatments — Fast Psoriasis Cure E—Book SCAM
Click here: http://www.sniplink.info/PSORIASIS7 for *much* more information.

By: ProductReviewsCB

Read the original:
Psoriasis Treatments — Fast Psoriasis Cure E—Book SCAM - Video

Psoriasis and street life
P.

By: nada jones

See the original post:
Psoriasis and street life - Video

How To Cure Psoriasis Fast — Fast Psoriasis Cure Review
Click here: http://www.sniplink.info/PSORIASIS7 for *much* more information.

By: ProductReviewsCB

Read more from the original source:
How To Cure Psoriasis Fast — Fast Psoriasis Cure Review - Video

How to Cure Psoriasis Naturally
I made this to help people cure their psoriasis. If you have psoriasis or you know anyone who does, you probably understand it is not a fun thing to deal wit...

By: Nicholas Lamborghini

See the original post here:
How to Cure Psoriasis Naturally - Video

Psoriasis - Rife Frequencies
Per your request! Drink more water than you feel you need to derive the most from these frequencies.

By: newtimer5

Continued here:
Psoriasis - Rife Frequencies - Video

Psoriasis Hell part 1
Healing Psoriasis Naturally.

By: Wellness4family

More here:
Psoriasis Hell part 1 - Video

Psoriasis, with its patches of itchy, flaky skin, is often nothing more than a benign cosmetic problem. Yet for many people its as disabling and threatening as rheumatoid arthritis or cancer.

These patients often dont tolerate existing medicines, or see them lose their power over time. Pharmaceutical companies, helped by a new understanding of the biology behind the disease, have developed a new class of drug candidates that may be faster and more effective for the more serious forms of psoriasis. The front runner, Novartis AG, said yesterday that its experimental treatment met the main goals of a late-stage study.

Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis, which causes pain and swelling in and around the joints, said Kristian Reich, a dermatologist in Hamburg who also teaches at the University of Goettingen.

This is a really serious inflammatory illness, like rheumatoid arthritis, except that it doesnt affect the joints, it affects the skin, Reich, who has tested the Novartis drug and two others in clinical trials, said in a telephone interview.

Its impossible to gauge the full toll of psoriasis on peoples lives. In addition to the physical pain and danger of complications are the psychological wounds.

These people dont get the jobs they should be getting, Reich said. They dont marry the partners they should be marrying.

About 125 million people worldwide have the skin condition, including 7.5 million Americans, according to the National Psoriasis Foundation. About 20 percent to 30 percent of them have a moderate to serious form of the disease, of which half are taking some kind of medicine, John Hohneker, who heads drug development for autoimmune diseases at Basel, Switzerland-based Novartis, said in an interview.

We know that 40 to 50 percent are dissatisfied with their current therapy, Hohneker said.

Novartiss therapy, secukinumab, worked significantly better than Amgen Inc.s Enbrel, the $3.7 billion-a-year drug that is considered the standard of care, in clearing the skin in a late-stage study, the company said yesterday in a statement. The research is being presented at the European Academy of Dermatology and Venereology meeting in Istanbul, which began Oct. 2.

Novartis shares fell 0.8 percent to 67.75 Swiss francs at 10:07 a.m. in Zurich trading today. The shares have gained about 18 percent this year, compared with a 15 percent gain on the Bloomberg European Pharmaceutical Index of 19 companies.

More:
Scaly Skin as Deadly as Cancer Spurs Psoriasis Treatment

Oct. 2, 2013 Universittsmedizin Berlin have discovered why patients with psoriasis are less susceptible to viral infections than patients suffering from atopic dermatitis (atopic eczema). The reason for this is the larger quantity of special proteins present in psoriatic skin, which inhibit viral replication. The interdisciplinary team under the direction of Dr. Robert Sabat from the Department of Dermatology and the Institute of Medical Immunology, in collaboration with the Institute of Virology and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), has additionally discovered a new function of the immune system. The study is published in the current issue of the journal Science Translational Medicine.

Psoriasis and atopic dermatitis are the two most common chronic diseases of the skin, from which over 40 million people suffer in the US and in EU alone. They cause persistent visible changes of the skin that severely impact the quality of life of the patients. In addition, the damaged skin barrier enables pathogens, such as viruses, to penetrate the skin and multiply. Surprisingly, only atopic dermatitis patients show a high incidence of cutaneous viral infections, which exacerbate the course of atopic dermatitis and if not treated promptly, might be life-threatening. The authors of the just-published study show that compared to the skin of patients with psoriasis, the skin of atopic dermatitis patients produces smaller quantities of what are known as antiviral proteins, which inhibit viral replication. In the search for the trigger responsible for these differences in protein production in the two skin diseases, the research team came upon the immune messenger interleukin-29.

"Of the thirty messengers produced by the immune cells that we examined in psoriatic skin, we only found a correlation with the quantities of antiviral proteins for interleukin-29," explains Dr. Kerstin Wolk from the Institute of Medical Immunology at the Charit, one of the study's two first authors. "In fact, interleukin-29 is present in psoriatic skin, but not in affected skin of atopic dermatitis patients." Removing this immune protein from skin samples taken from patients with psoriasis diminishes the quantity of antiviral proteins in these samples. Using experiments with healthy skin, skin models and isolated cells from the upper layer of the skin, the team additionally showed that interleukin-29 is able to stimulate the production of antiviral proteins, and thereby to protect the skin cells from viral infection.

Moreover, the researchers showed that interleukin-29 is produced by a specific population of immune cells known as Th17 cells. "These cells promote the production of antiviral proteins and thus, anti-viral defences in the skin cells," explains Dr. Katrin Witte from the Institute of Medical Immunology at the Charit, also a first author of the study. Thus, they simultaneously uncovered a new function of the immune system.

"It is conceivable that the therapeutic administration of interleukin-29 or substances that mimic its effects could increase patients' local defences against viruses. This would be applicable not only for atopic dermatitis, but also for other chronic inflammatory diseases that take place in epithelia, such as certain lung conditions in which viral infections represent a cofactor. This treatment could alleviate the course of such illnesses," states Dr. Robert Sabat, Head of the Psoriasis Research and Treatment Center at the Charit.

Go here to see the original:
Skin of patients with psoriasis protects itself from virus infections

BOUDRY, Switzerland--(BUSINESS WIRE)--

Celgene International Srl, a wholly-owned subsidiary of Celgene Corporation (CELG), today announced results of pre-specified sub-analyses from ESTEEM 1 on nail and scalp psoriasis, as well as health-related quality-of-life outcomes, from the Companys first phase III study in psoriasis, at the 22nd Congress of the European Academy of Dermatology and Venereology annual meeting in Istanbul, Turkey.

ESTEEM 1 is the largest of two registrational, randomized, placebo-controlled studies evaluating apremilast, an oral small-molecule specific inhibitor of phosphodiesterase 4 (PDE4), in more than 1,200 patients with moderate-to-severe plaque psoriasis. Previously reported findings from ESTEEM 1 showed that apremilast significantly improved general signs and symptoms of psoriasis across a wide-range of patient types.

Up to 55 percent of patients with psoriasis at any given time have nail involvement, and more than half have scalp psoriasis, which can be particularly debilitating for individuals dealing with this difficult-to-treat disease, said Professor Kristian Reich, M.D., SCIderm Research Institute and Dermatologikum, Hamburg, Germany. These analyses demonstrate that apremilast may improve these conditions and may offer a much-needed new oral treatment option for psoriasis patients. Moreover, the encouraging health-related quality-of-life findings suggest that long-term treatment with oral apremilast may improve the mental and physical well-being of these patients.

New analyses (abstract #2033) assessed the effects of apremilast on 558 patients in ESTEEM 1 with nail psoriasis and on 563 patients with at least moderate scalp psoriasis.

After 16 weeks of treatment, patients in the apremilast 30 mg twice daily (BID) group had significantly greater improvements in the Nail Psoriasis Severity Index (NAPSI) scores than the patients treated with placebo, showing an improvement of 22.5% vs. a worsening of 6.5%, respectively; P

Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID. After 16 weeks of therapy, significantly more patients treated with apremilast 30 mg achieved a ScPGA score of 0-1 (clear or almost clear) compared with those in the placebo group (46.5% vs. 17.5%, respectively; P

As shown in a separate analysis (abstract #0237), the treatment of 844 patients in ESTEEM 1 with apremilast also significantly improved health-related quality-of-life, as assessed by a variety of standardized measurements, including the Dermatology Quality of Life Index (DLQI), the Patient Health Questionnaire (PHQ-8), the European Quality of Life 5 Dimensions Questionnaire (EQ-5D), and the 36-item Short-Form Health Survey (SF-36) mental component summary (MCS).

Significant improvements in these measurement tools were seen after 16 weeks of treatment with apremilast; improvements were maintained through 32 weeks of treatment. Patients initially treated with placebo for 16 weeks who were then treated with apremilast for a subsequent 16 weeks also showed improvements in these measures.

In these analyses, the overall safety and tolerability profile of apremilast in patients with moderate to severe psoriasis was consistent with previously reported findings. The most commonly observed adverse events included diarrhea, nausea, upper respiratory tract infection, nasopharyngitis, tension headache, and headache. Adverse events were generally mild to moderate in severity. Nausea, vomiting, and diarrhea tended to occur most frequently during the first week of dosing and subsequently decreased. The discontinuation rate due to these AEs was low.

See the original post:
Oral Apremilast Significantly Improved Nail and Scalp Psoriasis and Health-Related Quality-of-Life Measures in Phase ...

Scalp Psoriasis Shampoo - Do They Really Work?
http://www.psoriasis101.org/scalp-psoriasis/scalp-psoriasis-shampoo/ - If you have been diagnosed with scalp psoriasis most likely your scalp psoriasis treatment will involve a psoriasis shampoo....

By: Scalp Psoriasis

See original here:
Scalp Psoriasis Shampoo - Do They Really Work? - Video